CAB39 Polyclonal Antibody
| Code | Size | Price |
|---|
| E-AB-13421-20uL | 20uL | £125.00 |
Quantity:
| E-AB-13421-60uL | 60uL | £172.00 |
Quantity:
| E-AB-13421-120uL | 120uL | £237.00 |
Quantity:
| E-AB-13421-200uL | 200uL | £344.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species:
- Human
- Mouse
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Shipping:
Ice packs
Storage:
-20°C
Further Information
Abbreviation:
CAB39
Background:
Peutz-Jeghers Syndrome (PJS) is a rare hereditary disease characterized by melanocytic macules of the lips, gastrointestinal hamartomatous polyps and an increased risk for many classes of cancer. The serine/threonine kinase LKB1 (also designated STK11) has been identified as the gene mutated in PJS. LKB1 activity increases upon the binding of a regulatory complex consisting of the STE20-related adaptor-alpha (STRAD alpha) pseudo kinase and the calcium binding protein 39 (MO25 alpha). STRAD and MO25 determine the subcellular localization of LKB1 by initiating its translocation from the nucleus to the cytoplasm, thus regulating the tumor suppressor activity of LKB1. The LKB1/STRAD/MO25 complex acts as an AMP-activated protein kinase kinase (AMPKK).
Buffer:
PBS with 0.05% sodium azide and 50% glycerol, PH7.4
Calculated MW:
40kDa
Concentration:
1.7 mg/mL
Conjugation:
Unconjugated
Dilution:
WB 1:500-1:2000, IHC 1:50-1:200
Immunogen:
Synthetic peptide of human CAB39
Purification method:
Affinity purification
Target Synonym:
Cab39;CAB39;Calcium binding protein 39;Calcium-binding protein 39;CGI 66;CGI-66;CGI66;MO25 alpha;MO25;Mouse protein 25 alpha;Protein Mo25
UNIProt ID:
Q9Y376